HRMY

28.46

1.86% 0.52

Dopo l'orario di chiusura: 28.46

Harmony Biosciences Holdings Inc (HRMY)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché HRMY Giù? Forum Previsione

Precedente Chiudi:

$27.94

Aprire:

$27.95

Volume 24 ore:

456.31K

Relative Volume:

0.69

Capitalizzazione di mercato:

$1.69B

Reddito:

$681.88M

Utile/perdita netta:

$122.63M

Rapporto P/E:

13.49

EPS:

2.11

Flusso di cassa netto:

$220.18M

1 W Prestazione:

-1.83%

1M Prestazione:

-17.07%

6M Prestazione:

-18.62%

1 anno Prestazione:

-2.50%

Intervallo 1D:

$27.95

$28.54

Intervallo di 1 settimana:

$27.56

$29.67

Portata 52W:

$26.47

$41.61

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Nome

Harmony Biosciences Holdings Inc

Settore

Healthcare (1151)

Industria

Biotechnology (660)

Telefono

(484) 539-9800

Indirizzo

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Dipendente

268

Cinguettio

Prossima data di guadagno

2024-10-29

Ultimi documenti SEC

HRMY's Discussions on Twitter

Confronta HRMY con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
HRMY Harmony Biosciences Holdings Inc	28.46	1.69B	681.88M	122.63M	220.18M	2.11
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-12-17	Iniziato	H.C. Wainwright	Buy
2024-10-10	Ripresa	Raymond James	Outperform
2024-09-10	Iniziato	UBS	Buy
2024-06-21	Iniziato	Citigroup	Buy
2024-01-02	Downgrade	BofA Securities	Neutral → Underperform
2023-09-25	Downgrade	Goldman	Neutral → Sell
2023-09-07	Iniziato	Berenberg	Buy
2023-04-20	Iniziato	BofA Securities	Neutral
2022-10-14	Aggiornamento	Janney	Neutral → Buy
2022-10-14	Aggiornamento	Jefferies	Hold → Buy
2022-08-03	Downgrade	Jefferies	Buy → Hold
2022-07-13	Downgrade	Goldman	Buy → Neutral
2022-07-07	Iniziato	Mizuho	Buy
2022-04-14	Iniziato	Cantor Fitzgerald	Overweight
2021-12-01	Iniziato	Oppenheimer	Outperform
2021-11-04	Iniziato	Raymond James	Outperform
2021-09-23	Iniziato	Needham	Buy
2021-03-29	Aggiornamento	Goldman	Neutral → Buy
2020-09-14	Iniziato	Goldman	Neutral
2020-09-14	Iniziato	Jefferies	Buy
2020-09-14	Iniziato	Piper Sandler	Overweight

Mostra tutto

Harmony Biosciences Holdings Inc Borsa (HRMY) Ultime notizie

03:52 AM

Harmony Biosciences Presents Positive Data on ZYN002 for Fragile X Syndrome - MSN

03:52 AM

Apr 17, 2025

Geode Capital Management LLC Has $31.08 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Apr 17, 2025

Apr 16, 2025

(HRMY) Technical Data - news.stocktradersdaily.com

Apr 16, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by JPMorgan Chase & Co. - Defense World

Apr 16, 2025

Franklin Resources Inc. Has $1.10 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Apr 16, 2025

Apr 12, 2025

Harmony Biosciences Appoints Ron Philip to Board of Directors - MSN

Apr 12, 2025

Apr 10, 2025

Harmony Biosciences (NASDAQ:HRMY) Earns “Buy” Rating from HC Wainwright - Defense World

Apr 10, 2025

Apr 08, 2025

Breaking Down Harmony Biosciences Hldgs: 13 Analysts Share Their Views - Benzinga

Apr 08, 2025

Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome - BioSpace

Apr 08, 2025

Oppenheimer maintains Harmony Biosciences Outperform rating By Investing.com - Investing.com South Africa

Apr 08, 2025

Developmental and Epileptic Encephalopathies Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire Inc.

Apr 08, 2025

Oppenheimer on Harmony Biosciences (HRMY): 'we remain pleased with WAKIX's 4Q24 performance' - StreetInsider

Apr 08, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Harmony Biosciences Holdings, Inc. (HRMY) And Encourages Shareholders to Connect - markets.businessinsider.com

Apr 08, 2025

Harmony Biosciences reports progress in Fragile X syndrome gel treatment - Investing.com

Apr 08, 2025

Breakthrough: New Fragile X Treatment Achieves 73% Success Rate in Long-term Study - Stock Titan

Apr 08, 2025

Apr 07, 2025

HRMY stock touches 52-week low at $27.87 amid market shifts By Investing.com - Investing.com South Africa

Apr 07, 2025

HRMY stock touches 52-week low at $27.87 amid market shifts - Investing.com India

Apr 07, 2025

Corebridge Financial Inc. Raises Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - Defense World

Apr 07, 2025

Vanguard Group Inc. Has $162.88 Million Stock Holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - The AM Reporter

Apr 07, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Stock Holdings Increased by Vanguard Group Inc. - Defense World

Apr 07, 2025

Arrowstreet Capital Limited Partnership Has $10.21 Million Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) - The AM Reporter

Apr 07, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Rating of “Buy” by Analysts - The AM Reporter

Apr 07, 2025

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Apr 07, 2025

Apr 06, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Harmony Biosciences Holdings, Inc. (HRMY) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Apr 06, 2025

Apr 04, 2025